Activist investment firm Ananym Capital Management plans to nominate as many as half a dozen directors to Henry Schein (HSIC), Reuters reported, citing three sources familiar with the matter.
According to the sources, Ananym told the dental and medical distributor that it needs to start searching for a new chief executive officer, cut costs, and optimize capital allocation.
In a November 18 Reuters report, Ananym projected more than $2.5 billion in proceeds from a potential divestment of Henry Schein's medical distribution business that could be used for repurchasing undervalued shares.
Earlier this month, Bank of America Securities adjusted their price target for Henry Schein's shares to $84 from $69 while upgrading the stock to buy.
Henry Schein did not immediately respond to MT Newswires' request for comment late on Wednesday.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。